167 related articles for article (PubMed ID: 17943077)
1. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.
Nagao S; Nishii K; Yoshihara D; Kurahashi H; Nagaoka K; Yamashita T; Takahashi H; Yamaguchi T; Calvet JP; Wallace DP
Kidney Int; 2008 Feb; 73(3):269-77. PubMed ID: 17943077
[TBL] [Abstract][Full Text] [Related]
2. Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease.
Cowley BD
Kidney Int; 2008 Feb; 73(3):251-3. PubMed ID: 18195694
[TBL] [Abstract][Full Text] [Related]
3. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
[TBL] [Abstract][Full Text] [Related]
4. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
[TBL] [Abstract][Full Text] [Related]
5. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.
Yamaguchi T; Wallace DP; Magenheimer BS; Hempson SJ; Grantham JJ; Calvet JP
J Biol Chem; 2004 Sep; 279(39):40419-30. PubMed ID: 15263001
[TBL] [Abstract][Full Text] [Related]
6. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Yamaguchi T; Nagao S; Wallace DP; Belibi FA; Cowley BD; Pelling JC; Grantham JJ
Kidney Int; 2003 Jun; 63(6):1983-94. PubMed ID: 12753285
[TBL] [Abstract][Full Text] [Related]
8. Expression of active B-Raf proto-oncogene in kidney collecting ducts induces cyst formation in normal mice and accelerates cyst growth in mice with polycystic kidney disease.
Parnell SC; Raman A; Zhang Y; Daniel EA; Dai Y; Khanna A; Reif GA; Vivian JL; Fields TA; Wallace DP
Kidney Int; 2022 Nov; 102(5):1103-1114. PubMed ID: 35760151
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP-mediated cyst expansion.
Wallace DP
Biochim Biophys Acta; 2011 Oct; 1812(10):1291-300. PubMed ID: 21118718
[TBL] [Abstract][Full Text] [Related]
10. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL
Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852
[TBL] [Abstract][Full Text] [Related]
12. Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin.
Nagao S; Morita M; Kugita M; Yoshihara D; Yamaguchi T; Kurahashi H; Calvet JP; Wallace DP
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1078-86. PubMed ID: 20719982
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
Nagao S; Kusaka M; Nishii K; Marunouchi T; Kurahashi H; Takahashi H; Grantham J
J Am Soc Nephrol; 2005 Jul; 16(7):2052-62. PubMed ID: 15888569
[TBL] [Abstract][Full Text] [Related]
14. L-type calcium channel modulates cystic kidney phenotype.
Jin X; Muntean BS; Aal-Aaboda MS; Duan Q; Zhou J; Nauli SM
Biochim Biophys Acta; 2014 Sep; 1842(9):1518-26. PubMed ID: 24925129
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.
Riwanto M; Kapoor S; Rodriguez D; Edenhofer I; Segerer S; Wüthrich RP
PLoS One; 2016; 11(1):e0146654. PubMed ID: 26752072
[TBL] [Abstract][Full Text] [Related]
16. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Yamaguchi T; Reif GA; Calvet JP; Wallace DP
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F944-51. PubMed ID: 20810616
[TBL] [Abstract][Full Text] [Related]
18. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
[TBL] [Abstract][Full Text] [Related]
19. Triptolide delays disease progression in an adult rat model of polycystic kidney disease through the JAK2-STAT3 pathway.
Jing Y; Wu M; Zhang D; Chen D; Yang M; Mei S; He L; Gu J; Qi N; Fu L; Li L; Mei C
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F479-F486. PubMed ID: 29513074
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Wang X; Gattone V; Harris PC; Torres VE
J Am Soc Nephrol; 2005 Apr; 16(4):846-51. PubMed ID: 15728778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
